학술논문
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Document Type
Article
Author
Venter, Willem D F ; Sokhela, Simiso; Simmons, Bryony; Moorhouse, Michelle; Fairlie, Lee; Mashabane, Nkuli; Serenata, Celicia; Akpomiemie, Godspower; Masenya, Masebole; Qavi, Ambar; Chandiwana, Nomathemba; McCann, Kaitlyn; Norris, Shane; Chersich, Matthew; Maartens, Gary; Lalla-Edward, Samanta; Vos, Alinda; Clayden, Polly; Abrams, Elaine; Arulappan, Natasha; Hill, Andrew
Source
In The Lancet HIV October 2020 7(10):e666-e676
Subject
Language
ISSN
2352-3018